GDF-15 at Admission Predicts Cardiovascular Death, Heart Failure, and Bleeding Outcomes in Patients with Coronary Artery Disease (CAD)
Authors' conclusion
In patients with CAD, admission levels of GDF-15 were associated with an increased 1 year risk of CV death, HF, and bleeding outcomes, but not with thrombotic events.
Study context
- Population
- Patients with CAD enrolled in the BIPass registry, China, November 2017 to September 2019
- Participants
- 6,322 patients
- Exposure
- Higher vs lower admission GDF-15 concentrations
- Outcome
- CV death, thrombotic events (MI, ischaemic stroke), HF events (acute HF during hospitalization or hospitalization for HF post-discharge [A/H HF], cardiogenic shock) and bleeding (non-CABG-related major bleeding, clinically significant bleeding [CSB])
- Follow-up
- 12 months after hospitalization
Methodological detailsmulticentre, 5 tertiary hospitals in China, consecutive enrolment
- Multicentre
- 5 tertiary hospitals in China
- Consecutive enrolment
Main finding
As reported in the abstract
Association of higher GDF-15 with outcomes:
- Adjusted for clinical risk factors
- Prognostic biomarkers
Higher GDF-15Hazard ratio (95% CI)P value
CV death
1.98(1.35–2.88)
P < 0.001A/H HF
2.69(1.92–3.77)
P < 0.001Cardiogenic shock
1.46(1.04–2.05)
P = 0.029CSB
1.48(1.22–1.79)
P < 0.001- Median admission GDF-15 1091 ng/L (IQR 790.5-1635.0)
- 1091
Observational data: associations, not effects.
Further findings
Net reclassification with GDF-15 added to risk factors and biomarkers
- Improved net reclassification for cardiovascular (CV) death, A/H heart failure (HF), cardiogenic shock and clinically significant bleeding (CSB)
Original publication
GDF-15 at Admission Predicts Cardiovascular Death, Heart Failure, and Bleeding Outcomes in Patients with CAD. ESC Heart Fail. Published 24 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →